BES_Mark.jpg
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockholders and Encourages Investors to Contact the Firm
February 24, 2024 02:30 ET | Bragar Eagel & Squire
NEW YORK, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Biogen Inc. (“Biogen” or...
Neurologists Report
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
February 22, 2024 15:04 ET | Spherix Global Insights
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation...
Final Logo-01.png
Spinal Muscular Atrophy Market: Navigating Therapeutic Advances towards USD 5.6 Billion by 2034, with a CAGR of 14.80% - By PMI
February 15, 2024 17:02 ET | PMI
Covina, Feb. 15, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Spinal Muscular Atrophy Market size was valued at about USD 1.4 Billion in 2024 and expected to grow at CAGR of...
Final Logo-01.png
Anti-CD20 Monoclonal Antibodies Market Size & Share to Exceed USD 19.8 Billion by 2034, at CAGR of 9.0%. “Revolutionizing Immune Therapies: Unveiling the Global Symphony of Anti-CD20 Monoclonal Antibodies Market” – PMI Leads the Way
February 01, 2024 20:00 ET | PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Anti-CD20 Monoclonal Antibodies Market size was valued at about USD 9.0 Billion in 2024 and expected to grow at...
US Neurologists Emph
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
November 07, 2023 10:41 ET | Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
How High Is the Bar
How High Is the Bar for Future ALS Treatments? Although Neurologists Express Frustration with Current Treatments, They Are Quick to Adopt Therapies that Promise to Delay ALS Progression
August 02, 2023 11:15 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 02, 2023 (GLOBE NEWSWIRE) -- A quiet but significant advance was made during the last year: not one, but two medicines were FDA approved to delay disease progression in the...
Alectos Logo big(1).jpg
Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
June 06, 2022 07:30 ET | Alectos Therapeutics Inc.
Cambridge, Mass. and Burnaby, British Columbia , June 06, 2022 (GLOBE NEWSWIRE) -- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
March 27, 2022 21:00 ET | Bragar Eagel & Squire
NEW YORK, March 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
March 21, 2022 21:00 ET | Bragar Eagel & Squire
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
BES_Mark.jpg
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra and Encourages Investors to Contact the Firm
March 16, 2022 21:00 ET | Bragar Eagel & Squire
NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...